BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 11454421)

  • 1. Changes in gene expression during progression of ovarian carcinoma.
    Tapper J; Kettunen E; El-Rifai W; Seppälä M; Andersson LC; Knuutila S
    Cancer Genet Cytogenet; 2001 Jul; 128(1):1-6. PubMed ID: 11454421
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular subtypes of serous borderline ovarian tumor show distinct expression patterns of benign tumor and malignant tumor-associated signatures.
    Curry EW; Stronach EA; Rama NR; Wang YY; Gabra H; El-Bahrawy MA
    Mod Pathol; 2014 Mar; 27(3):433-42. PubMed ID: 23948749
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired FHIT expression characterizes serous ovarian carcinoma.
    Ozaki K; Enomoto T; Yoshino K; Fujita M; Buzard GS; Kawano K; Yamasaki M; Murata Y
    Br J Cancer; 2001 Jul; 85(2):247-54. PubMed ID: 11461085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene expression profiles in three histologic types, clear-cell, endometrioid and serous ovarian carcinomas.
    Pamuła-Piłat J; Rubel T; Rzepecka IK; Olbryt M; Herok R; Dansonka-Mieszkowska A; Grzybowska E; Kupryjańczyk J
    J Biol Regul Homeost Agents; 2014; 28(4):659-74. PubMed ID: 25620176
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunohistochemical localization of metallothionein in benign and malignant epithelial ovarian tumors.
    McCluggage WG; Strand K; Abdulkadir A
    Int J Gynecol Cancer; 2002; 12(1):62-5. PubMed ID: 11860537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of latent transforming growth factor-beta 1 (TGF-beta 1) binding protein 1 (LTBP-1) in association with TGF-beta 1 in ovarian carcinoma.
    Higashi T; Sasagawa T; Inoue M; Oka R; Shuangying L; Saijoh K
    Jpn J Cancer Res; 2001 May; 92(5):506-15. PubMed ID: 11376559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation.
    Choi YL; Kim J; Kwon MJ; Choi JS; Kim TJ; Bae DS; Koh SS; In YH; Park YW; Kim SH; Ahn G; Shin YK
    Histol Histopathol; 2007 Nov; 22(11):1185-95. PubMed ID: 17647191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Micropapillary serous carcinoma of the ovary has distinct patterns of chromosomal imbalances by comparative genomic hybridization compared with atypical proliferative serous tumors and serous carcinomas.
    Staebler A; Heselmeyer-Haddad K; Bell K; Riopel M; Perlman E; Ried T; Kurman RJ
    Hum Pathol; 2002 Jan; 33(1):47-59. PubMed ID: 11823973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary.
    Bonome T; Lee JY; Park DC; Radonovich M; Pise-Masison C; Brady J; Gardner GJ; Hao K; Wong WH; Barrett JC; Lu KH; Sood AK; Gershenson DM; Mok SC; Birrer MJ
    Cancer Res; 2005 Nov; 65(22):10602-12. PubMed ID: 16288054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy.
    Santin AD; Zhan F; Bellone S; Palmieri M; Cane S; Bignotti E; Anfossi S; Gokden M; Dunn D; Roman JJ; O'Brien TJ; Tian E; Cannon MJ; Shaughnessy J; Pecorelli S
    Int J Cancer; 2004 Oct; 112(1):14-25. PubMed ID: 15305371
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling.
    Gilks CB; Vanderhyden BC; Zhu S; van de Rijn M; Longacre TA
    Gynecol Oncol; 2005 Mar; 96(3):684-94. PubMed ID: 15721412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characterization of the molecular differences between ovarian endometrioid carcinoma and ovarian serous carcinoma.
    Madore J; Ren F; Filali-Mouhim A; Sanchez L; Köbel M; Tonin PN; Huntsman D; Provencher DM; Mes-Masson AM
    J Pathol; 2010 Feb; 220(3):392-400. PubMed ID: 19967725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical detection of p53 protein in borderline and malignant serous ovarian tumors.
    Klemi PJ; Takahashi S; Joensuu H; Kiilholma P; Narimatsu E; Mori M
    Int J Gynecol Pathol; 1994 Jul; 13(3):228-33. PubMed ID: 7928055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
    Tan Y; Sinniah R; Bay BH; Singh G
    J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MicroRNA expression profiles in serous ovarian carcinoma.
    Nam EJ; Yoon H; Kim SW; Kim H; Kim YT; Kim JH; Kim JW; Kim S
    Clin Cancer Res; 2008 May; 14(9):2690-5. PubMed ID: 18451233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification by cDNA microarray of genes involved in ovarian carcinogenesis.
    Ono K; Tanaka T; Tsunoda T; Kitahara O; Kihara C; Okamoto A; Ochiai K; Takagi T; Nakamura Y
    Cancer Res; 2000 Sep; 60(18):5007-11. PubMed ID: 11016619
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma.
    Cui X; Li L; Yan G; Meng K; Lin Z; Nan Y; Jin G; Li C
    BMC Cancer; 2015 Apr; 15():244. PubMed ID: 25885439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profiling of advanced-stage serous ovarian cancers distinguishes novel subclasses and implicates ZEB2 in tumor progression and prognosis.
    Yoshihara K; Tajima A; Komata D; Yamamoto T; Kodama S; Fujiwara H; Suzuki M; Onishi Y; Hatae M; Sueyoshi K; Fujiwara H; Kudo Y; Inoue I; Tanaka K
    Cancer Sci; 2009 Aug; 100(8):1421-8. PubMed ID: 19486012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential gene expression profiles between tumor biopsies and short-term primary cultures of ovarian serous carcinomas: identification of novel molecular biomarkers for early diagnosis and therapy.
    Bignotti E; Tassi RA; Calza S; Ravaggi A; Romani C; Rossi E; Falchetti M; Odicino FE; Pecorelli S; Santin AD
    Gynecol Oncol; 2006 Nov; 103(2):405-16. PubMed ID: 16725184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular abnormalities in ovarian carcinoma: clinical, morphological and therapeutic correlates.
    Gurung A; Hung T; Morin J; Gilks CB
    Histopathology; 2013 Jan; 62(1):59-70. PubMed ID: 23240670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.